Abstract
The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) was the first prospective, double-blind, randomized trial to assess specifically the antiatherosclerotic potential of a calcium antagonist in coronary artery segments with minimal, angiographic disease.1 Unanticipated reductions in prospectively defined clinical events (mainly hospitalization for unstable angina pectoris and the need for percutaneous coronary interventions [PCI]) were noted. We undertook this post hoc analysis to assess the association between angiographic findings and clinical events.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
